Innate Pharma S.A. ADR (IPHA) Stock Price, Quote & News

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 4 30 30 30 30

Fax: 33 4 30 30 30 00

Website: www.innate-pharma.com

Address:

117, Avenue de Luminy, BP 30191, Marseille, France

dgbio May. 15 at 3:15 PM

$IPHA Preclinical but it can get into clinic very quickly because monalizumab is extensively tested already. Pulmonary fibrosis is important. This could be huge. https://www.science.org/doi/10.1126/scitranslmed.adq5442

0 · Reply

James_West_1965 May. 15 at 1:22 PM

$IPHA High demand in PM. Recently, on Level II, I've seen tens of thousands of shares of traders wanting to buy in. The bid-ask difference has become very tight, all signaling high demand in the regular session.

0 · Reply

nopennys May. 14 at 9:55 PM

$IPHA Yannis Morel, Chief Operating Officer, Innate Pharma: Turning to slide 22. Slide 22 summarizes the financial highlights of our AstraZeneca partnerships. For monalizumab, the agreements amount up to EUR 1.275 billion of milestones. We have already received EUR 450 million and remain eligible to additional EUR 825 million of potential payments. In case monalizumab is approved, AstraZeneca will book sales, and Innate Pharma will receive double-digit royalties on sales in the U.S. and rest of the world. In Europe, since Innate Pharma is contributing to 30% of the funding for the phase III trial, we will get 50% of the profit and have the option to co-promote the drug. For IPH5201, the agreement is worth up to EUR 885 million in milestones. To date, we already received EUR 60 million and remain eligible to EUR 825 million

0 · Reply

alert716 May. 14 at 9:49 PM

$TANH I told you, just heating up 🤑🤑🤑 $TDIC $BIYA $IPHA

0 · Reply

topstockalerts May. 14 at 7:40 PM

Top Gainers PT2 $DXF $BXDC $YMAT $CBRS $IPHA

0 · Reply

neo55 May. 14 at 6:39 PM

$IPHA already has strong validation from AstraZeneca, which owns roughly 6 million shares at around a $6 average and has committed up to $500M+ in milestone payments tied to one partnered drug alone. With multiple pipeline assets, advancing Phase 3 programs, and growing strategic importance in immuno-oncology, Innate Pharma increasingly looks like a logical long-term acquisition target for AstraZeneca. If the clinical data continues to improve, a full buyout would not be surprising

0 · Reply

dgbio May. 14 at 6:14 PM

$IPHA Looks like they're in a bidding process for this: 'We are very confident that we will execute a, either a BD partnership or a royalty financing partnership for lacutamab. The discussions are quite advanced and we would expect to be able to conclude one of those two types of partnerships moving forward in the relatively short term. From our perspective, it doesn't really matter which way we go with either a BD partnership or a royalty financing partnership... We'll make that decision in the coming future, basically based on what's best for the company in terms of the NPVs of the two different approaches'.

0 · Reply